INmune Bio Bolsters Board with Rare-Disease and BD Executives Ahead of Ebstrocel Launch
Event summary
- INmune Bio adds R. Duane Clark II (Sanofi Rare Diseases GM) and James Sapirstein (ex-Gilead, ex-Tobira Therapeutics) to its Board of Directors.
- Clark brings 40+ years of rare-disease commercialization experience, including leading Sanofi’s $1B+ U.S. rare-disease portfolio.
- Sapirstein has led 6 global product launches and structured transactions totaling ~$1.7B, including Tobira’s acquisition by Allergan.
- Appointments aim to strengthen Ebstrocel™ commercialization planning and business development for INmune Bio’s pipeline.
- Ebstrocel™ regulatory filings planned for UK MHRA (2026) and EU EMA (2027), with U.S. BLA submission also in progress.
The big picture
INmune Bio is fortifying its leadership ahead of critical regulatory and commercial milestones for Ebstrocel™, its lead asset for recessive dystrophic epidermolysis bullosa (RDEB). The appointments reflect a strategic pivot toward rare-disease commercialization and business development, aligning with industry trends where specialized expertise is increasingly critical for biotech companies navigating complex regulatory pathways and market access challenges. With Ebstrocel™ poised for regulatory filings in 2026/2027, the board additions signal INmune Bio’s focus on translating clinical progress into commercial success.
What we're watching
- Commercialization Strategy
- How Clark’s rare-disease expertise will shape Ebstrocel’s market access and pricing strategy ahead of potential 2026/2027 regulatory filings.
- Business Development
- Whether Sapirstein’s transaction experience can accelerate partnerships or licensing deals for INmune Bio’s pipeline.
- Execution Risk
- The pace at which INmune Bio can integrate board-level strategic guidance into operational readiness for Ebstrocel’s launch.
Related topics